Skip to main content

BioMarin Pharmaceutical (BMRN) Receives a Buy from Bernstein

Tipranks - Tipranks - Fri Feb 20, 6:44AM CST

Bernstein analyst William Pickering maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $90.00. The company’s shares closed yesterday at $61.83.

President's Day Sale - 70% Off

According to TipRanks, Pickering is a 3-star analyst with an average return of 5.0% and a 61.18% success rate. Pickering covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Regeneron, and BridgeBio Pharma.

In addition to Bernstein, BioMarin Pharmaceutical also received a Buy from Wells Fargo’s Mohit Bansal in a report issued yesterday. However, on February 17, H.C. Wainwright reiterated a Hold rating on BioMarin Pharmaceutical (NASDAQ: BMRN).

See Insiders’ Hot Stocks on TipRanks >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).